Takeda Pharmaceutical Co. Ltd.’s blockbuster gastrointestinal drug Entyvio (vedolizumab) has been approved in Japan, as a treatment and maintenance therapy for moderately to severely active ulcerative colitis (UC) in patients with an inadequate response to conventional (TNF-alpha antagonist) treatment.
The product was given formal clearance by the country's Ministry of Health, Labour and Welfare following an earlier positive review panel recommendation in a batch of final approvals that also included two new
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?